good start to the week, page-34

Hi Katana,

yes, I sold out a little while back but still keeping an eye on PXS. Have to say though that I sense this may not be the blockbuster we had all hoped for years back. Bronchiectasis is the big one of course so that will be the company maker/breaker in my opinion. Will be interesting though to see the take up of this by CF patietns (which depends on whether their specialists are convinced about it I guess). The very poor performance of aridol shows that it can be tough to break into an established market when the alternative you are offering has only an incremental and/or debatable improvement to offer.